This is a multi-site prospective, single arm, observational study examining the outcomes of robotic pancreaticoduodenectomy.
This is a multi-site prospective, single arm, observational study examining the outcomes of robotic pancreaticoduodenectomy. Adult patients with symptomatic benign, premalignant, or resectable malignant pathologies recommended for resection after multidisciplinary review and have already chosen to have robotic surgery will be evaluated for enrolling into the study. Relevant operative, postoperative, and pathologic outcomes will be collected prospectively. The well-established enhanced recovery after pancreaticoduodenectomy pathway currently used in our institution will be applied to all patients postoperatively.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
91
The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
Johns Hopkins Hospital
Baltimore, Maryland, United States
Atrium Health
Charlotte, North Carolina, United States
Length of hospital stay
Days from date of intervention to discharge
Time frame: up to 90 days post intervention
Time to functional recovery
Days to functional recovery, which requires that all the following are met: * Pain controlled on oral analgesics only (Yes/no, only the date when the result first changes from No to Yes will be recorded) * Able to maintain ≥50% of required caloric intake * No need for intravenous fluids for hydration * Return to independent mobility or baseline mobility for those with previous mobility deficits
Time frame: Day 1 post-intervention to functional recovery
Number of participants experiencing complications
Number of participants who experience Clavien-Dindo Grade III or higher complications
Time frame: Day 90 post-intervention
Operative estimated blood loss
Blood loss during the surgery (unit: ml)
Time frame: During the surgery
Number of participants experiencing pancreaticoduodenectomy-specific complications
Number of participants who experience complications including pancreatic fistula, delayed gastric emptying, postoperative bleeding, wound infection, bile leak, chyle leak, other gastrointestinal leakage, re-intervention (radiographic,surgical, endoscopic), 30-day mortality, 90-day mortality.
Time frame: Day 90 post-intervention
Pathological outcomes as assessed by Pathological response to neoadjuvant therapy
Pathological response to neoadjuvant therapy(if there is any) reported by pathologist reviewing the resected surgical specimen. Pathological outcomes as defined by Protocol for Examination of Specimens from Patients with Carcinoma of the Pancreas (Pancreas Exocrine 4.0.0.1), where: complete response (score 0) is no viable cancer cells; marked response/minimal residual cancer (score 1) is presence of single cells or rare small groups of cancer cells; moderate response (score 2) is residual cancer with evident tumor regression, but more than single cells or rare groups of cancer cells; poor or no response (score 3) is extensive residual cancer with no evident tumor regression.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 90-post intervention
Survival Outcome
Recurrence free outcome is from surgery to recurrence.
Time frame: Overall survival is from surgery to last time of follow-up or death, assessed up to 60 months-post intervention.
Quality of life (QoL) as measured by EQ-5D-3L
The EQ-5D-3L questionnaire essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.This decision results into a 1-digit number that expresses the level selected for that dimension. Numbers range from 1-3, with a higher number reflected more problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state', ranging from 0 to 100. A higher score reflects a worse health state.
Time frame: EQ-5D-3L will be measured at 2 to 4 weeks and 3 to 6 months-post intervention.
Quality of life (QoL) as measured by QLQ-C30 (version 3)
QLQ-C30 questionnaire includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100. A higher score represents a higher response level.
Time frame: QLQ-C30 will be measured at 2 to 4 weeks and 3 to 6 months-post intervention.
Exploratory outcomes
Comprehensive complication index (CCI) is calculated using the multiple complication information within 30 days after the surgery. Each complication included in the index will be recorded as yes or no, and a Clavien-Dindo Grade will be recorded for each complication marked as yes.
Time frame: 30 days after the surgery